Document is current
Any future updates will be listed below
-
Authors
Bradbury, Charlotte A. https://orcid.org/0000-0001-5248-8165
Lawler, Patrick R.
McVerry, Bryan J.
Zarychanski, Ryan
,
Al-Beidh, Farah
Angus, Derek C.
Arabi, Yaseen M.
Aryal, Diptesh
Annane, Djillali
Beane, Abi
Berry, Lindsay R.
Berry, Scott
Bhimani, Zahra
Bihari, Shailesh
Bonten, Marc J. M.
Bradbury, Charlotte A.
Brunkhorst, Frank M.
Buxton, Meredith
Buzgau, Adrian
Carrier, Marc
Cheng, Allen C.
Cove, Matthew
Derde, Lennie P. G.
Detry, Michelle A.
Estcourt, Lise J.
Fergusson, Dean A.
Fitzgerald, Mark
Fowler, Robert A.
Girard, Timothy D.
Goligher, Ewan C.
Goossens, Herman
Gordon, Anthony C.
Green, Cameron
Haniffa, Rashan
Higgins, Alisa M.
Hills, Thomas
Huang, David T.
Horvat, Christopher M.
Hunt, Beverley J.
Ichihara, Nao
Jayakumar, Devachandran
Kumar, Anand
Laffan, Michael A.
Lamontagne, Francois
Lawler, Patrick R.
Leavis, Helen L.
Lewis, Roger J.
Linstrum, Kelsey M.
Litton, Edward
Lorenzi, Elizabeth
Lother, Sylvain A.
Marshall, John C.
McArthur, Colin J.
McAuley, Daniel F.
McGlothlin, Anna
McGuinness, Shay P.
Middeldorp, Saskia
Murthy, Srinivas
McQuilten, Zoe
McVerry, Bryan J.
Mouncey, Paul R.
Neal, Matthew D.
Nichol, Alistair D.
Parke, Rachael L.
Parker, Jane C.
Patanwala, Asad
Reyes, Luis
Rowan, Kathryn M.
Saito, Hiroki
Santos, Marlene S.
Saunders, Christina T.
Schutgens, Roger E. G.
Serpa-Neto, Ary
Seymour, Christopher W.
Shankar-Hari, Manu
Singh, Vanessa
Stanworth, Simon J.
Tolppa, Timo
Turgeon, Alexis F.
Turner, Anne M.
van Bentum-Puijk, Wilma
van de Veerdonk, Frank L.
Webb, Steve A.
- License Information
-
More Information
Article History
Accepted: 5 May 2023
First Online: 31 May 2023
Declarations
:
: PRL and RZ report no conflict of interest. BM reports grant funding from NIH/NHLBI, Translational Breast Cancer Research Foundation, UPMC Learning While Doing Program and Bayer; personal fees for consulting from Boehringer Ingelheim, Synairgen Research, Ltd and BioAegis, Inc. and payment for expert testimony from VeraMedica Institute, LLC. CAB reports personal fees for consulting from Bayer, BMS Pfizer, Lilly, Novartis, Amgen and honoraria for lectures from Bayer, BMS Pfizer, Janssen, Lilly, Novartis, Amgen, Sanofi.
: The REMAP-CAP platform trial has been approved by the relevant ethics committees in all regions and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Free to read: This content has been made available to all.
